Display options
Cite
Konvalinka A, Batruch I, Tokar T, et al. Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clin Proteomics. 2016;13:16doi: 10.1186/s12014-016-9117-x.
Konvalinka, A., Batruch, I., Tokar, T., Dimitromanolakis, A., Reid, S., Song, X., Pei, Y., Drabovich, A. P., Diamandis, E. P., Jurisica, I., & Scholey, J. W. (2016). Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clinical proteomics, 1316. https://doi.org/10.1186/s12014-016-9117-x
Konvalinka, Ana, et al. "Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring." Clinical proteomics vol. 13 (2016): 16. doi: https://doi.org/10.1186/s12014-016-9117-x
Konvalinka A, Batruch I, Tokar T, Dimitromanolakis A, Reid S, Song X, Pei Y, Drabovich AP, Diamandis EP, Jurisica I, Scholey JW. Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring. Clin Proteomics. 2016 Aug 05;13:16. doi: 10.1186/s12014-016-9117-x. eCollection 2016. PMID: 27499720; PMCID: PMC4974759.
Copy Download .nbib Format: NLM
Share it on

Clin Proteomics. 2016 Aug 05;13:16. doi: 10.1186/s12014-016-9117-x. eCollection 2016.

Quantification of angiotensin II-regulated proteins in urine of patients with polycystic and other chronic kidney diseases by selected reaction monitoring.

Clinical proteomics

Ana Konvalinka, Ihor Batruch, Tomas Tokar, Apostolos Dimitromanolakis, Shelby Reid, Xuewen Song, York Pei, Andrei P Drabovich, Eleftherios P Diamandis, Igor Jurisica, James W Scholey

Affiliations

  1. Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, 11-PMB-189, 585 University Avenue, Toronto, ON M5G 2N2 Canada ; Toronto General Research Institute, University Health Network, Toronto, Canada.
  2. Department of Laboratory Medicine and Pathobiology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
  3. Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
  4. Toronto General Research Institute, University Health Network, Toronto, Canada.
  5. Division of Genomic Medicine, University Health Network, University of Toronto, Toronto, Canada.
  6. Department of Laboratory Medicine and Pathobiology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada ; Department of Clinical Biochemistry, University Health Network, University of Toronto, Toronto, Canada.
  7. Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada ; Departments of Medical Biophysics and Computer Science, University Health Network, University of Toronto, Toronto, Canada.

PMID: 27499720 PMCID: PMC4974759 DOI: 10.1186/s12014-016-9117-x

Abstract

BACKGROUND: Angiotensin-II (Ang II) mediates progression of autosomal-dominant polycystic kidney disease (ADPKD) and other chronic kidney diseases (CKD). However, markers of kidney Ang II activity are lacking. We previously defined 83 Ang II-regulated proteins in vitro, which reflected kidney Ang II activity in vivo.

METHODS: In this study, we developed selected reaction monitoring (SRM) assays for quantification of Ang II-regulated proteins in urine of ADPKD and CKD patients. We demonstrated that 47 of 83 Ang II-regulated transcripts were differentially expressed in cystic compared to normal kidney tissue. We then developed SRM assays for 18 Ang II-regulated proteins overexpressed in cysts and/or secreted in urine. Methods that yielded CV ≤ 6 % for control proteins, and recovery ~100 % were selected. Heavy-labeled peptides corresponding to 13 identified Ang II-regulated peptides were spiked into urine samples of 17 ADPKD patients, 9 patients with CKD predicted to have high kidney Ang II activity and 11 healthy subjects. Samples were then digested and analyzed on triple-quadrupole mass spectrometer in duplicates.

RESLUTS: Calibration curves demonstrated linearity (R(2) > 0.99) and within-run CVs < 9 % in the concentration range of 7/13 peptides. Peptide concentrations were normalized by urine creatinine. Deamidated peptide forms were monitored, and accounted for <15 % of the final concentrations. Urine excretion rates of proteins BST1, LAMB2, LYPA1, RHOB and TSP1 were significantly different (p < 0.05, one-way ANOVA) between patients with CKD, those with ADPKD and healthy controls. Urine protein excretion rates were highest in CKD patients and lowest in ADPKD patients. Univariate analysis demonstrated significant association between urine protein excretion rates of most proteins and disease group (p < 0.05, ANOVA) as well as sex (p < 0.05, unpaired t test). Multivariate analysis across protein concentration, age and sex demonstrated good separation between ADPKD and CKD patients.

CONCLUSIONS: We have optimized methods for quantification of Ang II-regulated proteins, and we demonstrated that they reflected differences in underlying kidney disease in this pilot study. High urine excretion of Ang II-regulated proteins in CKD patients likely reflects high kidney Ang II activity. Low excretion in ADPKD appears related to lack of communication between cysts and tubules. Future studies will determine whether urine excretion rate of Ang II-regulated proteins correlates with kidney Ang II activity in larger cohorts of chronic kidney disease patients.

Keywords: Angiotensin II; Autosomal dominant polycystic kidney disease; Chronic kidney disease; Polycystic kidney disease; Proteomics; Renin angiotensin system; Selected reaction monitoring; Urine

References

  1. BMC Nephrol. 2015 Jun 20;16:86 - PubMed
  2. J Am Soc Nephrol. 2003 Jun;14(6):1578-83 - PubMed
  3. J Am Soc Nephrol. 2009 Sep;20(9):1888-93 - PubMed
  4. J Am Soc Nephrol. 2000 Feb;11(2):319-29 - PubMed
  5. Am J Pathol. 2007 Sep;171(3):777-89 - PubMed
  6. Kidney Int. 2005 Jan;67(1):265-71 - PubMed
  7. Clin J Am Soc Nephrol. 2013 Jul;8(7):1089-97 - PubMed
  8. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8545-51 - PubMed
  9. Proteomics. 2011 Mar;11(6):1160-71 - PubMed
  10. Kidney Int. 2014 May;85(5):1068-77 - PubMed
  11. Am J Kidney Dis. 2006 May;47(5):751-60 - PubMed
  12. Sci Transl Med. 2012 Jul 11;4(142):142ra94 - PubMed
  13. J Mol Med (Berl). 2001 Jul;79(7):382-9 - PubMed
  14. Sci Transl Med. 2013 Nov 20;5(212):212ra160 - PubMed
  15. Kidney Int. 2003 Feb;63(2):678-85 - PubMed
  16. Nat Methods. 2012 May 30;9(6):555-66 - PubMed
  17. J Biol Chem. 2005 Feb 18;280(7):5343-9 - PubMed
  18. J Chromatogr B Biomed Appl. 1994 Dec 9;662(2):261-78 - PubMed
  19. Nephrol Dial Transplant. 1996 Feb;11(2):263-9 - PubMed
  20. Acta Physiol (Oxf). 2015 Mar;213(3):740-6 - PubMed
  21. Am J Pathol. 2015 May;185(5):1423-35 - PubMed
  22. Am J Kidney Dis. 1994 Feb;23(2):247-54 - PubMed
  23. Kidney Int. 2012 Apr;81(8):784-90 - PubMed
  24. Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):944-9 - PubMed
  25. Kidney Int. 1992 Aug;42(2):364-73 - PubMed
  26. J Am Soc Nephrol. 1994 Aug;5(2):215-23 - PubMed
  27. Kidney Int. 1988 Jun;33(6):1084-90 - PubMed
  28. Hum Mol Genet. 2009 Jul 1;18(13):2328-43 - PubMed
  29. J Biol Chem. 2013 Aug 23;288(34):24834-47 - PubMed
  30. Mol Cell Proteomics. 2012 Aug;11(8):422-34 - PubMed
  31. Kidney Int. 1992 May;41(5):1311-9 - PubMed
  32. J Am Soc Nephrol. 2010 Aug;21(8):1254-62 - PubMed
  33. Nephrol Dial Transplant. 2012 Aug;27(8):3176-81 - PubMed
  34. Mol Cell Proteomics. 2011 Dec;10(12):M110.004127 - PubMed
  35. Am J Nephrol. 2013;38(3):218-25 - PubMed
  36. J Biol Chem. 1996 Sep 13;271(37):22570-7 - PubMed
  37. Mol Cell Proteomics. 2012 Dec;11(12):1709-23 - PubMed
  38. Am J Physiol Renal Physiol. 2004 Feb;286(2):F278-87 - PubMed
  39. J Clin Invest. 1987 Aug;80(2):443-57 - PubMed
  40. Lancet. 2008 Aug 16;372(9638):547-53 - PubMed
  41. Bioinformatics. 2010 Apr 1;26(7):966-8 - PubMed
  42. Nephrol Dial Transplant. 2012 Apr;27(4):1607-13 - PubMed
  43. N Engl J Med. 2006 May 18;354(20):2122-30 - PubMed
  44. Am J Physiol Renal Physiol. 2008 Aug;295(2):F515-24 - PubMed
  45. Proteomics. 2011 Mar;11(6):1135-47 - PubMed
  46. Physiol Genomics. 2004 Sep 16;19(1):106-16 - PubMed
  47. Anal Chem. 2010 Dec 15;82(24):10116-24 - PubMed
  48. Adv Chronic Kidney Dis. 2013 Sep;20(5):390-5 - PubMed
  49. J Am Soc Nephrol. 2007 May;18(5):1558-65 - PubMed
  50. J Am Soc Nephrol. 2016 Jun;27(6):1702-13 - PubMed
  51. Steroids. 2010 Aug-Sep;75(8-9):550-4 - PubMed
  52. J Am Soc Nephrol. 2012 Jul;23(7):1181-9 - PubMed
  53. J Am Soc Nephrol. 2002 Jul;13(7):1733-9 - PubMed
  54. Mol Syst Biol. 2008;4:222 - PubMed
  55. Kidney Int. 1995 Dec;48(6):1818-27 - PubMed
  56. Nat Methods. 2014 Feb;11(2):149-55 - PubMed
  57. J Proteome Res. 2014 Feb 7;13(2):1077-87 - PubMed
  58. Circ Res. 1988 Oct;63(4):748-57 - PubMed
  59. Am J Nephrol. 2001 Mar-Apr;21(2):98-103 - PubMed
  60. J Proteome Res. 2010 Mar 5;9(3):1236-45 - PubMed
  61. N Engl J Med. 2013 Nov 14;369(20):1892-903 - PubMed
  62. Am J Physiol Renal Physiol. 2012 Jun 1;302(11):F1374-84 - PubMed
  63. Am J Pathol. 2003 Oct;163(4):1261-73 - PubMed
  64. J Proteome Res. 2014 Feb 7;13(2):875-82 - PubMed
  65. Kidney Int. 1990 Dec;38(6):1177-80 - PubMed

Publication Types